| Entry |
|
|---|
| Name |
Valziflocept (USAN) |
|---|
| Formula |
C876H1337N241O270S4
|
|---|
| Exact mass |
19680.7181
|
|---|
| Mol weight |
19692.71
|
|---|
| Sequence |
APPKAVLKLE PQWINVLQED SVTLTCRGTH SPESDSIQWF HNGNLIPTHT QPSYRFKANN
NDSGEYTCQT GQTSLSDPVH LTVLSEWLVL QTPHLEFQEG ETIVLRCHSW KDKPLVKVTF
FQNGKSKKFS RSDPNFSIPQ ANHSHSGDYH CTGNIGYTLY SSKPVTITVQ APSSSP
(Disulfide bridge: 26-68, 107-151) |
|---|
| Type |
Peptide |
|---|
| Efficacy |
Immunomodulator |
|---|
| Comment |
Treatment of systemic lupus erythematosus (SLE)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04662 | B cell receptor signaling pathway |
| hsa04666 | Fc gamma R-mediated phagosome formation |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Organismal systems
Immune system
FCGR2B (CD32)
D11339 Valziflocept (USAN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
